Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tovaxin open-label extension in MS
NCT00595920Phase 2Terminated
- Sponsor
- Opexa Therapeutics
- Start
- Nov 2007
- Primary completion
- Dec 2008
- Modality
- Native Immune Cells, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tovaxin in multiple sclerosis (MS) and clinically isolated syndrome (CIS), sponsored by Opexa Therapeutics. Primary endpoint: Changes in Number of Combined Unique Active Lesions on Brain Magnetic Resonance Imaging (MRI) at 1 year. Started Nov 2007; status: terminated.
02
Drugs
tovaxin
03
Conditions
multiple sclerosis (MS)clinically isolated syndrome (CIS)
Beyond the preview
Go deeper on NCT00595920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00595920.